Posted inBiotechnology
Cullgen ditches reverse merger with Pulmatrix to go with Gyre in $300M buyout
Over a year after first agreeing to a reverse merger with Pulmatrix, protein degradation biotech Cullgen has instead opted to…
Posted inBiotechnology
UniQure shares crash 40% as FDA rejects early approval path for Huntington’s gene therapy
Shares of uniQure plummeted more than 40% in premarket trading Monday after the company confirmed the FDA has rejected its…
Posted inBiotechnology
FDA fully releases clinical hold on Intellia CRISPR gene therapy trials
The FDA has liberated the second of two Intellia Therapeutics clinical trials that were put on hold last October following…
Posted inBiotechnology
United Therapeutics’ phase 3 win tees up filing to challenge J&J in cardiac condition
United Therapeutics has linked a once-daily drug candidate to a 55% drop in the risk of clinical worsening in a phase…
Posted inBiotechnology
KCTD1 Boosts PD-L1, Weakening Liver Cancer Immunity
In a groundbreaking study published recently in Cell Death Discovery, researchers have unveiled a pivotal molecular mechanism that sheds new…
Posted inBiotechnology
BioAtla lays off 70% of workforce, searches for buyers for antibody pipeline
BioAtla is laying off 70% of its workforce as the antibody biotech mulls whether to sell off its remaining assets.…
Posted inBiotechnology
Ultrasound Protocol Reduces Brain Bleeds in Preemies
Intraventricular hemorrhage (IVH) is recognized as one of the most daunting complications affecting extremely preterm infants, a vulnerable population whose…
Posted inBiotechnology
Tackling Food Insecurity to Combat Dyslipidemia
In a groundbreaking exploration of the intricate interplay between metabolic disorders and social determinants of health, researchers Ruiz Bejar, Ward,…
Posted inBiotechnology
Children with Poor Oral Health Face Higher Risk of Cardiovascular Disease in Adulthood, Study Finds
Emerging research from the University of Copenhagen reveals a compelling connection between childhood oral health and the risk of developing…
Posted inBiotechnology
Lynk points to phase 3 eczema win as more proof of next-gen JAK inhibitor’s potential
Lynk Pharmaceuticals has reported another phase 3 win in China for its next-gen JAK inhibitor, this time hitting skin clearance…